Physician
Rehabilitation & Occupational Medicine LLC
Rehabilitation & Occupational Medicine LLC was paid $3.11M by Medicaid between Jan 2018 and Nov 2024, across 83 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 27% of everything it billed.
33Billing provider infoREHABILITATION & OCCUPATIONAL MEDICINE LLC
LAS CRUCES, NM 88011
LAS CRUCES, NM 88011
33aNPI1205981339assigned 01/25/2007
33bProvider typePhysical Medicine & Rehabilitation Physician
28Total paid$3.11M
24GClaims73,007
24DCodes billed83
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Physical Medicine & Rehabilitation Physician providers in New Mexico
Rank by total paid#1 of 20
Median peer was paid$104K
This provider vs. median30×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,427 | $382K | |
| 2019 | 12,426 | $377K | |
| 2020 | 8,786 | $361K | |
| 2021 | 21,007 | $1.00M | |
| 2022 | 11,172 | $554K | |
| 2023 | 3,759 | $210K | |
| 2024incomplete | 2,430 | $221K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 27% | 11,012 | 9,454 | $848K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 18% | 7,205 | 6,651 | $558K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 7,524 | 6,420 | $436K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 10% | 6,095 | 5,589 | $325K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 5.8% | 7,048 | 6,518 | $181K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.2% | 2,312 | 662 | $129K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.4% | 1,216 | 390 | $73K |
| 99490 | Ccm add 20min | 2.2% | 2,161 | 2,155 | $69K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.6% | 2,061 | 645 | $48K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.2% | 252 | 248 | $37K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.2% | 1,495 | 1,356 | $36K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.1% | 375 | 373 | $35K |
71 more codes
| 95886 | <1% | 249 | $30K | |
| 97014 | <1% | 1,813 | $27K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,085 | $17K |
| 99487 | Ccm add 20min | <1% | 249 | $16K |
| 80053 | Comprehensive metabolic panel | <1% | 1,594 | $15K |
| 95911 | <1% | 64 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 793 | $12K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 643 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,651 | $11K |
| 99443 | <1% | 76 | $11K | |
| 76881 | <1% | 99 | $11K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 666 | $10K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,786 | $10K |
| 97010 | <1% | 689 | $9K | |
| 0012A | <1% | 213 | $9K | |
| 96101 | <1% | 142 | $9K | |
| 99072 | <1% | 176 | $8K | |
| 0011A | <1% | 240 | $8K | |
| 97162 | <1% | 179 | $8K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 94 | $7K |
| 80061 | Lipid panel | <1% | 514 | $6K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 529 | $6K |
| 95117 | <1% | 649 | $6K | |
| 94375 | <1% | 166 | $5K | |
| 96127 | <1% | 653 | $5K | |
| 80050 | General health panel | <1% | 99 | $5K |
| 99442 | <1% | 42 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 231 | $4K |
| 82575 | <1% | 563 | $4K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 253 | $3K |
| 80305 | <1% | 345 | $3K | |
| 90688 | <1% | 190 | $3K | |
| 99205 | Prolong outpt/office vis | <1% | 12 | $3K |
| G0506 | Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | <1% | 121 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 274 | $2K |
| 81003 | <1% | 1,886 | $2K | |
| 85651 | <1% | 626 | $2K | |
| 0064A | <1% | 50 | $2K | |
| 82948 | <1% | 494 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 103 | $2K |
| 99489 | Ccm add 20min | <1% | 47 | $1K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 34 | $1K |
| 86140 | <1% | 229 | $950.54 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 27 | $785.23 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 18 | $769.24 |
| 97035 | <1% | 67 | $693.69 | |
| 99050 | <1% | 46 | $659.46 | |
| 99439 | <1% | 14 | $599.98 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 333 | $521.09 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 25 | $513.84 |
| 95921 | <1% | 12 | $460.32 | |
| 81025 | <1% | 48 | $383.06 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13 | $371.92 |
| 90756 | <1% | 12 | $363.31 | |
| 82962 | <1% | 122 | $349.82 | |
| 72100 | <1% | 12 | $340.61 | |
| 36416 | <1% | 184 | $214.24 | |
| 81001 | <1% | 107 | $188.46 | |
| 93000 | <1% | 13 | $180.86 | |
| 81007 | <1% | 12 | $144.00 | |
| G0008 | Administration of influenza virus vaccine | <1% | 24 | $101.02 |
| 99408 | <1% | 32 | $82.92 | |
| 84550 | <1% | 12 | $50.80 | |
| J3490 | Unclassified drugs | <1% | 61 | $41.89 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15 | $10.50 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 15 | $8.28 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 59 | $3.19 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 1,111 | $0.02 |
| 1160F | 0% | 114 | $0.00 | |
| 1159F | 0% | 119 | $0.00 | |
| 82565 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDELAHOUSSAYE, BRIAN (MEDICAL DIRECTOR/OWNER)